NCT07322159
IASO206 in Patients With Relapsed/Refractory Multiple Myeloma
StatusRecruiting
PhaseEarly Phase 1
Primary completion (estimated)
At risk: Primary completion moved 2 months later.
See at-risk trials from Institute of Hematology & Blood Diseases Hospital, China
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Enrollment increased: 12 → 18 participants
- Notable Recruitment opened
- Eligibility criteria expanded, about 45 words
- Primary completion pushed from Oct 15, 2026 to Dec 15, 2026
- Start date changed from estimate of Jan 15, 2026 to Jan 8, 2026
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
The incidence and severity of adverse events（AEs）
Timeframe: up to 2 years after IASO206 infusion
Secondary (8)
Overall response rate (ORR)
Time to response (TTR)
MRD negativity rate
Duration of response (DOR)
Progression-free survival (PFS)
Show 3 moreShow less
Overall survival (OS)
Pharmacodynamics（PD）
Pharmacokinetic Analysis（PK）
Arms and interventions
IASO206Active comparator
IASO206 will be administered in one infusion.
Drugs: IASO206 injection
Sites
1 site in 1 country
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical SciencesTianjin, China